Precision oncology considers the molecular characteristics of a patient’s tumor to determine an ideal approved or investigational therapy that could provide clinical benefit. While prospective profiling of patients' tumors has resulted in improved selection and response to therapies, this “tumorcentric” approach can fail to account for the impact of the complex microenvironment that influences tumor growth and response to therapy. The gut microbiota is a complex ecosystem of microorganisms. These microbes play fundamental roles in health and survival and have been found to play a significant role in the response to cancer therapy and susceptibility to toxic side effects of those drugs. In this webinar, we will explore the use of syngeneic mouse models and supplementation with microbiota to enhance immune modulation.
TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit TD2inc.com.
Paul Gonzales has twenty years of experience working in oncology drug development. Mr. Gonzales has been with TD2 for more than 10 years working with biotech clients and maturing the nonclinical research department. His vast experience in preclinical models contributes to the design and execution of TD2 clients’ preclinical development plans. Mr. Gonzales has aided in the advancement of many current oncology treatments during their early development phase. He trained in the oncology drug development field at the Cancer Therapy and Research Center. Mr. Gonzales received his Bachelor of Science in Biomedical Sciences from Texas A&M University in College Station.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.